Watch LNAI. Know when insiders buy.
One email the day a filing lands. Free.
LNAI
Lunai Bioworks Inc.
2.33
+0.05 +2.42%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
24
FLAG · shorts 24
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $84.5MP/E 1.1DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$128.3MNET CASH $3.1M52W 1.47 – 13.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Mar 31 | $21K | — | 100.0% | −$1.5M | −$2.6M | −1459.3% | -0.10 | −$1M | $0 | −$1M | May 15 |
| Q2 2026 · Dec 31 | — | — | — | −$1.8M | −$1.8M | — | -0.08 | −$1.1M | — | — | May 15 |
| Q1 2026 · Sep 30 | — | — | — | −$3.3M | $2.8M | — | 0.13 | −$1.3M | — | — | May 15 |
| Q4 2025 · Jun 30derived | — | — | — | −$126.9M | −$126.7M | — | 2.10 | −$1.8M | — | — | Sep 29 |
| Q3 2025 · Mar 31 | — | — | — | −$4.2M | $189K | — | 0.00 | −$1.5M | — | — | May 15 |
| Q2 2025 · Dec 31 | — | — | — | −$4.5M | −$7.3M | — | -0.45 | −$2.6M | — | — | May 15 |
| Q1 2025 · Sep 30 | — | — | — | −$53.3M | −$44.2M | — | -2.76 | −$2M | — | — | May 15 |
| Q4 2024 · Jun 30derived | — | — | — | −$17.1M | −$15.7M | — | 0.00 | −$2.4M | $24K | −$2.4M | Sep 29 |
| Q3 2024 · Mar 31 | — | — | — | −$51.4M | −$59M | — | -0.54 | −$2.6M | $5K | −$2.6M | May 15 |
| Q2 2024 · Dec 31 | — | — | — | −$4.3M | −$4.5M | — | -0.07 | −$3.1M | — | — | May 15 |
| Q1 2024 · Sep 30 | — | — | — | −$8.9M | −$9.2M | — | -0.14 | −$2.8M | — | — | May 15 |
| Q4 2023 · Jun 30derived | — | — | — | −$22.9M | −$23.2M | — | -0.41 | −$2.3M | $6K | −$2.3M | Feb 19 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Jun 30 | — | — | −$189M | −$178M | — | -1.08 | −$7.9M | — | — | — | — |
| FY2024 · to Jun 30 | — | — | −$81.6M | −$88.4M | — | -0.91 | −$11M | $70K | −$11M | — | — |
| FY2023 · to Jun 30 | — | — | −$38.6M | −$39.7M | — | -0.71 | −$11.8M | $30K | −$11.8M | — | — |
| FY2022 · to Jun 30 | — | — | −$116.1M | −$113.4M | — | -2.16 | −$15.7M | $5K | −$15.7M | — | — |
| FY2021 · to Jun 30 | — | — | −$23.4M | −$26.7M | — | -0.57 | −$20.6M | $49K | −$20.7M | — | — |
| FY2020 · to Jun 30 | — | — | −$11.9M | −$11.4M | — | -0.25 | −$10.5M | $184K | −$10.6M | — | — |
Every number comes from Lunai Bioworks Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.